Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H. Airas L, et al. Among authors: hartung hp. Ther Adv Neurol Disord. 2024 Apr 17;17:17562864241233041. doi: 10.1177/17562864241233041. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38638671 Free PMC article. Review.
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review.
Fernández Ó, Sörensen PS, Comi G, Vermersch P, Hartung HP, Leocani L, Berger T, Van Wijmeersch B, Oreja-Guevara C. Fernández Ó, et al. Among authors: hartung hp. Front Immunol. 2024 Apr 5;15:1379538. doi: 10.3389/fimmu.2024.1379538. eCollection 2024. Front Immunol. 2024. PMID: 38646534 Free PMC article. Review.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Among authors: hartung hp. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
Editorial: CNS autoimmune disorders and COVID-19.
Mirmosayyeb O, Badihian S, Shaygannejad V, Hartung HP. Mirmosayyeb O, et al. Among authors: hartung hp. Front Neurol. 2023 Apr 4;14:1183998. doi: 10.3389/fneur.2023.1183998. eCollection 2023. Front Neurol. 2023. PMID: 37082445 Free PMC article. No abstract available.
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BA; N-MOmentum study investigators. Aktas O, et al. Among authors: hartung hp. J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):757-768. doi: 10.1136/jnnp-2022-330412. Epub 2023 May 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 37221052 Free PMC article. Clinical Trial.
1,122 results